ATE455545T1 - Medizinische zusammensetzungen zur intravesikalen behandlung von blasenkrebs - Google Patents

Medizinische zusammensetzungen zur intravesikalen behandlung von blasenkrebs

Info

Publication number
ATE455545T1
ATE455545T1 AT09075067T AT09075067T ATE455545T1 AT E455545 T1 ATE455545 T1 AT E455545T1 AT 09075067 T AT09075067 T AT 09075067T AT 09075067 T AT09075067 T AT 09075067T AT E455545 T1 ATE455545 T1 AT E455545T1
Authority
AT
Austria
Prior art keywords
formulation
bladder cancer
medical compositions
intravesical treatment
azaridinyl
Prior art date
Application number
AT09075067T
Other languages
English (en)
Inventor
Bastiaan Nuijen
Ernie Pfadenhauer
Jos F Beijen
Original Assignee
Spectrum Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Spectrum Pharmaceuticals Inc filed Critical Spectrum Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE455545T1 publication Critical patent/ATE455545T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT09075067T 2001-11-01 2002-11-01 Medizinische zusammensetzungen zur intravesikalen behandlung von blasenkrebs ATE455545T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US34444601P 2001-11-01 2001-11-01

Publications (1)

Publication Number Publication Date
ATE455545T1 true ATE455545T1 (de) 2010-02-15

Family

ID=23350584

Family Applications (2)

Application Number Title Priority Date Filing Date
AT09075067T ATE455545T1 (de) 2001-11-01 2002-11-01 Medizinische zusammensetzungen zur intravesikalen behandlung von blasenkrebs
AT06077149T ATE493126T1 (de) 2001-11-01 2002-11-01 Medizinische zusammensetzungen zur intravesikalen behandlung von blasenkrebs

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT06077149T ATE493126T1 (de) 2001-11-01 2002-11-01 Medizinische zusammensetzungen zur intravesikalen behandlung von blasenkrebs

Country Status (13)

Country Link
US (6) US6894071B2 (de)
EP (3) EP2060259B1 (de)
JP (1) JP4317452B2 (de)
AT (2) ATE455545T1 (de)
AU (1) AU2002350115A1 (de)
CA (2) CA2466148C (de)
CY (1) CY1111252T1 (de)
DE (2) DE60238798D1 (de)
DK (2) DK2060259T3 (de)
ES (2) ES2341922T3 (de)
HK (1) HK1132181A1 (de)
PT (2) PT2060259E (de)
WO (1) WO2003037314A2 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6894071B2 (en) * 2001-11-01 2005-05-17 Spectrum Pharmaceuticals, Inc. Medical compositions for intravesical treatment of bladder cancer
US8563592B2 (en) 2001-11-01 2013-10-22 Spectrum Pharmaceuticals, Inc. Bladder cancer treatment and methods
US8361490B2 (en) 2004-09-16 2013-01-29 Theracoat Ltd. Biocompatible drug delivery apparatus and methods
AU2006230582A1 (en) * 2005-03-31 2006-10-05 Spectrum Pharmaceuticals, Inc. Indoloquinone tumor radiation sensitization
US9346029B2 (en) 2005-06-06 2016-05-24 The University Of British Columbia Polymer-based serum albumin substitute
AU2007213476B2 (en) * 2006-02-09 2013-03-28 Spectrum Pharmaceuticals, Inc. Bladder cancer treatment involving determination of tumor enzyme level
CA2669138A1 (en) * 2006-11-09 2008-12-04 University Of Maryland, Baltimore Use of 5,6-dimethylxanthenone-4-acetic acid as an antimicrobial agent
AU2008224962B2 (en) * 2007-03-13 2013-07-25 Spectrum Pharmaceuticals, Inc. Intravesical apaziquone administration following transurethral resection for treating cancer
GB0800311D0 (en) * 2008-01-09 2008-02-20 Cytosystems Ltd Apparatus and method for filtering biological material
EP2525777B1 (de) 2010-01-20 2019-05-29 UroGen Pharma Ltd. Material und verfahren zur behandlung von internen hohlräumen
JP5914366B2 (ja) 2010-03-01 2016-05-11 ザ ユニヴァーシティ オヴ ブリティッシュ コロンビア 誘導体化超分岐ポリグリセロール類
PL2619331T3 (pl) * 2010-09-22 2018-10-31 The Board Of Regents Of The University Of Texas System Sposoby leczenia nowotworu obejmujące ukierunkowanie na nqo1
WO2013011504A1 (en) 2011-07-20 2013-01-24 Theracoat Ltd. Materials and method for treating internal body cavities
HUE032240T2 (en) 2011-10-24 2017-09-28 Asana Biosciences Llc cyclohexylamines
WO2014062856A1 (en) 2012-10-16 2014-04-24 Halozyme, Inc. Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
CA2933811C (en) 2013-12-16 2021-02-09 Asana Biosciences, Llc P2x3 and/or p2x2/3 compounds and methods
CN104743887B (zh) * 2014-09-22 2016-03-23 巨石集团有限公司 一种玻璃纤维组合物及其玻璃纤维和复合材料
CN109996546B (zh) 2016-09-30 2023-06-27 阿沙纳生物科学公司 P2x3和/或p2x2/3化合物及方法
EP3924521A4 (de) 2019-02-15 2023-03-29 IncellDx, Inc. Test von blasenassoziierten proben, identifizierung und behandlung von blasenassoziierter neoplasie und kits zur verwendung darin
CN112220742A (zh) * 2019-07-15 2021-01-15 深圳艾欣达伟医药科技有限公司 稳定的ast-3424注射液制剂及制备方法

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3993754A (en) * 1974-10-09 1976-11-23 The United States Of America As Represented By The United States Energy Research And Development Administration Liposome-encapsulated actinomycin for cancer chemotherapy
JPS54151134A (en) 1978-05-19 1979-11-28 Kureha Chem Ind Co Ltd Antitumorigenic agent
NL8001280A (nl) * 1980-03-04 1981-10-01 Philips Nv Lagedrukontladingslamp.
AU565354B2 (en) 1983-11-14 1987-09-10 Bio-Mimetics Inc. Bioadhesive compositions and methods of treatment therewith
US4898729A (en) 1983-12-09 1990-02-06 Euroceltique, S.A. Treatment of hypertension, compounds and compositions for antihypertension and diuresis
US4671954A (en) * 1983-12-13 1987-06-09 University Of Florida Microspheres for incorporation of therapeutic substances and methods of preparation thereof
JPS60163621A (ja) 1984-02-02 1985-08-26 村上　俊文 紙製便座カバ−の製造方法
JPS60163821A (ja) 1984-02-03 1985-08-26 Tdk Corp フエライト粒子を含む薬剤用担体
JPS61189215A (ja) 1985-02-18 1986-08-22 Teijin Ltd ５−フルオロ−２′−デオキシウリジンエステル類の油状医薬組成物
JPH0819095B2 (ja) * 1986-04-17 1996-02-28 スペッカンプ、ウィレム・ニコ インドロキノン化合物
US4871542A (en) 1987-04-30 1989-10-03 Ferring Service Center, N.V. Method and apparatus useful for delivering medicinal compositions into the bladder and urinary tract
EP0331635A3 (de) 1988-02-29 1990-02-28 The Board of Regents of the University of Texas System Zubereitungen zur Behandlung von Blasenkrebs.
EP0338679A3 (de) 1988-03-24 1991-03-06 Genentech, Inc. Tumor Necrosis Faktor zur Behandlung von Blasenkrebs
FR2629584B1 (fr) 1988-03-31 1993-06-04 France Etat Armement Dispositif de stabilisation pour un projectile a faible moment d'inertie longitudinal tire a partir d'un tube raye
US5843156A (en) 1988-08-24 1998-12-01 Endoluminal Therapeutics, Inc. Local polymeric gel cellular therapy
US5744166A (en) 1989-02-25 1998-04-28 Danbiosyst Uk Limited Drug delivery compositions
PT93772A (pt) * 1989-04-17 1991-01-08 Searle & Co Processo para a preparacao de composicoes para o tratamento de neoplasias, contendo um agente anti-neoplastico, por exemplo doxorubicina e um agente protector para reduzir os efeitos secundarios, por exemplo carbetimer
US5216011A (en) * 1989-09-01 1993-06-01 Bristol-Myers Squibb Co. Stable solutions of mitomycin c
FI84874C (fi) 1989-11-02 1992-02-10 Valio Meijerien Foerfarande foer inkapsling av biologiskt aktiva aemnen, enligt metoden framstaelld kapsel, dess anvaendning och foder innehaollande den.
US5237466A (en) 1989-11-02 1993-08-17 International Business Machines Corporation Method and apparatus for programmably controlling spindle synchronization and phase among disk drives in a storage subsystem
US5292516A (en) 1990-05-01 1994-03-08 Mediventures, Inc. Body cavity drug delivery with thermoreversible gels containing polyoxyalkylene copolymers
US5346703A (en) 1990-08-07 1994-09-13 Mediventures, Inc. Body cavity drug delivery with thermo-irreversible polyoxyalkylene and ionic polysaccharide gels
IT1250421B (it) 1991-05-30 1995-04-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato con proprieta' bio-adesive.
US5550110A (en) 1992-04-22 1996-08-27 Warner-Lambert Company Endothelin Antagonists II
JP3598049B2 (ja) 1992-09-18 2004-12-08 山之内製薬株式会社 ハイドロゲル徐放性製剤
US5744155A (en) 1993-08-13 1998-04-28 Friedman; Doron Bioadhesive emulsion preparations for enhanced drug delivery
EP0642797B1 (de) 1993-09-09 2000-05-17 Takeda Chemical Industries, Ltd. Formulierung enthaltend einen antibakteriellen und einen Antiulcus Wirkstoff
CA2135151A1 (en) 1993-11-08 1995-05-09 Mitsuhiro Wakimasu Cyclic hexapeptides, their production and use
US5405622A (en) 1993-12-22 1995-04-11 Vernice; Joseph Gamma radiation resistant lubricating gel
TW438601B (en) 1994-05-18 2001-06-07 Janssen Pharmaceutica Nv New mucoadhesive emulsion compositions and a process for the preparation thereof
US5811416A (en) 1994-06-06 1998-09-22 Board Of Regents The University Of Texas System Endothelin antagonist and/or endothelin synthase inhibitor in combination with a progestin, an estrogen, a cyclooxygenase inhibitor, or a nitric acid donor or substrate
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
ATE532530T1 (de) 1994-12-12 2011-11-15 Omeros Corp Bespüllungslösung und deren verwendung zur perioperativen hemmung von schmerzen, entzündungen und/oder spasmen an einer gefässstruktur
US5749845A (en) 1995-01-25 1998-05-12 Iotek, Inc. Delivering an agent to an organ
AU1166097A (en) 1995-12-21 1997-07-17 British Technology Group Limited Indoloquinone derivatives as bioreductive agents
US5985312A (en) 1996-01-26 1999-11-16 Brown University Research Foundation Methods and compositions for enhancing the bioadhesive properties of polymers
AU712953B2 (en) 1996-03-11 1999-11-18 Focal, Inc. Polymeric delivery of radionuclides and radiopharmaceuticals
US5955096A (en) 1996-06-25 1999-09-21 Brown University Research Foundation Methods and compositions for enhancing the bioadhesive properties of polymers using organic excipients
EP0815870A3 (de) 1996-06-27 2000-05-03 Takeda Chemical Industries, Ltd. Zubereitung für die Vorbeugung und Behandlung des Schlaganfalls
JP2967734B2 (ja) * 1996-10-18 1999-10-25 日本電気株式会社 薄膜の形成方法
KR20010006027A (ko) 1997-04-03 2001-01-15 포인트 바이오메디칼 코퍼레이션 방광내 약물 송달 시스템
US5854382A (en) 1997-08-18 1998-12-29 Meadox Medicals, Inc. Bioresorbable compositions for implantable prostheses
WO1999012547A1 (en) * 1997-09-08 1999-03-18 Theramark Limited Treatment of inflammatory conditions
US6156744A (en) 1998-03-19 2000-12-05 Cancer Research Campaign Tech (London) DT-diaphorase directed anti-tumor agents
EP0950418A2 (de) 1998-04-14 1999-10-20 Takeda Chemical Industries, Ltd. Zusammensetzung zur Prävention und Behandlung von ischämischen Erkrankungen
US6171610B1 (en) 1998-04-24 2001-01-09 University Of Massachusetts Guided development and support of hydrogel-cell compositions
AU739140B2 (en) 1998-05-05 2001-10-04 Astrazeneca Ab Mycobacterial inhibitors
IL124957A0 (en) 1998-06-16 1999-01-26 Univ Ben Gurion Active ingredient delivery systems and devices based on porous matrices
US6087396A (en) 1998-10-05 2000-07-11 Situs Corporation Oxybutynin formulations and method of use
GB9827034D0 (en) 1998-12-10 1999-02-03 Univ Manchester Delivery formulation
JP2000256182A (ja) 1999-03-03 2000-09-19 Kazuhiro Morimoto 抗菌製剤
AU4978100A (en) 1999-04-29 2000-11-17 Coley Pharmaceutical Gmbh Screening for immunostimulatory dna functional modifyers
US7566452B1 (en) 1999-05-04 2009-07-28 New York University Cancer treatment with endothelin receptor antagonists
US6545048B1 (en) 1999-06-29 2003-04-08 California Institute Of Technology Compositions and methods of treating cancer using compositions comprising an inhibitor or endothelin receptor activity
MXPA02010764A (es) 2000-05-31 2003-03-10 Warner Lambert Co Combinaciones de un antagonista del receptor endotelina y un compuesto antiepileptico que tiene propiedades para aliviar el dolor o analgesico.
AU3652102A (en) 2000-12-01 2002-06-11 Guilford Pharm Inc Compounds and their uses
AU2002241736A1 (en) 2000-12-21 2002-07-01 Bristol-Myers Squibb Company Method for preventing or treating pain by administering an endothelin antagonist
WO2003009805A2 (en) 2001-07-23 2003-02-06 Brigham And Women's Hospital, Inc. Analgesic methods using endothelin receptor ligands
US6894071B2 (en) 2001-11-01 2005-05-17 Spectrum Pharmaceuticals, Inc. Medical compositions for intravesical treatment of bladder cancer
US7973064B2 (en) 2001-11-27 2011-07-05 The Board Of Trustees Of The University Of Illinois Method and composition for potentiating an opiate analgesic
US20040009918A1 (en) 2002-05-03 2004-01-15 Hanne Nedergaard Stabilised solid compositions of modified factor VII
ES2377959T3 (es) 2002-05-03 2012-04-03 Novo Nordisk Health Care Ag Composiciones sólidas estabilizadas de factor VII modificado
JP2006508086A (ja) 2002-10-24 2006-03-09 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ イリノイ 固形腫瘍を予防および治療するための方法および組成物
SI1912675T1 (sl) 2005-07-25 2014-07-31 Emergent Product Development Seattle, Llc zmanjšanje števila celic B z uporabo molekul, ki se specifično vežejo na CD37 in CD20
AU2007213476B2 (en) 2006-02-09 2013-03-28 Spectrum Pharmaceuticals, Inc. Bladder cancer treatment involving determination of tumor enzyme level

Also Published As

Publication number Publication date
JP2005532986A (ja) 2005-11-04
CA2789114C (en) 2014-03-25
HK1132181A1 (en) 2010-02-19
PT1864660E (pt) 2011-03-31
EP1864660A2 (de) 2007-12-12
DE60235214D1 (de) 2010-03-11
EP1439835A2 (de) 2004-07-28
CA2466148C (en) 2013-01-08
ES2384208T3 (es) 2012-07-02
ES2341922T3 (es) 2010-06-29
JP4317452B2 (ja) 2009-08-19
DK1864660T3 (da) 2011-02-21
PT2060259E (pt) 2010-04-26
US20050215615A1 (en) 2005-09-29
EP2060259A1 (de) 2009-05-20
DE60238798D1 (de) 2011-02-10
EP2060259B1 (de) 2010-01-20
DK2060259T3 (da) 2010-05-17
US7977369B2 (en) 2011-07-12
ATE493126T1 (de) 2011-01-15
CA2789114A1 (en) 2003-05-08
US20090076123A1 (en) 2009-03-19
US20030133954A1 (en) 2003-07-17
EP1864660B1 (de) 2010-12-29
US20080166402A1 (en) 2008-07-10
WO2003037314A3 (en) 2003-10-16
US6894071B2 (en) 2005-05-17
CA2466148A1 (en) 2003-05-08
EP1864660A3 (de) 2008-04-23
WO2003037314A2 (en) 2003-05-08
US20120252861A1 (en) 2012-10-04
US20070010570A1 (en) 2007-01-11
AU2002350115A1 (en) 2003-05-12
CY1111252T1 (el) 2015-08-05
US8648108B2 (en) 2014-02-11

Similar Documents

Publication Publication Date Title
HK1132181A1 (en) Medical compositions for intravesical treatment of bladder cancer
CY1123084T1 (el) Θεραπεια των ασθενειων αποθηκευσης γλυκογονου τυπου ιι
MY140488A (en) Substituted oxazolidinones and their use in the field of blood coagulation
WO2003096990A3 (en) Protein cages for the delivery of medical imaging and therapy
WO2002002518A3 (en) Compounds to treat alzheimer's disease
EA200201247A1 (ru) Соединения для лечения болезни альцгеймера
WO2002002520A8 (en) Compounds to treat alzheimer's disease
LU91928I2 (fr) Ipilimumab et ses dérivés pharmaceutiquement acceptables (YERVOY®)
NO20044475L (no) 2-(2,6-diklorfenyl)-diarulimidazoler
EA200300845A1 (ru) Модифицированные антитела и способы применения
WO2001052847A8 (en) Thiazole, imidazole and oxazole compounds and treatments of disorders associated with protein aging
NO20034204L (no) Farmasöytiske kombinasjoner til behandling av kreft
ATE451123T1 (de) Vaginal verabreichbare zusammensetzung zur behandlung von uteriner dysrhythmie
ATE355288T1 (de) Verbindungen und therapeutische methoden
DE60137635D1 (de) Verwendung von allopurinol zur behandlung von bluthochdruck
DE60219614D1 (de) 3, 7 thiaprostansäurederivate als mittel zur verminderung des augeninnendruckes
DOP2002000451A (es) Nuevas ciclohexilsulfonas (agentes terapéuticos)
WO2003022203A3 (en) Products and methods for treating microbial infections
DE69727691D1 (de) Verwendung von keratinocyten-wachstumsfaktor-2
WO2002015897A3 (en) Use of sublethal concentrations of anti-invasin compounds to therapeutically or prophylactically treat fungal infections
SE9902596D0 (sv) Pharmaceutically active compounds
CA2458932A1 (en) Methylene-4-azasteroids
RU99115516A (ru) Средство для коррекции кроветворения, профилактики и лечения диспепсии телят

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 2060259

Country of ref document: EP